Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
iX Biopharma Ltd. ( (SG:42C) ) has issued an announcement.
iX Biopharma has been named one of Singapore’s Fastest Growing Companies 2026 by The Straits Times and Statista, marking the third time it has received this recognition after earlier listings in 2023 and 2024, underscoring its strong revenue growth and business resilience. The company attributes its momentum to its WaferiX drug delivery platform and is pursuing a capital-light expansion strategy in the United States, including a proprietary digital platform targeting the longevity segment, a move that positions it for scalable long-term growth and reinforces its industry standing among high-growth healthcare innovators.
The most recent analyst rating on (SG:42C) stock is a Sell with a S$0.18 price target. To see the full list of analyst forecasts on iX Biopharma Ltd. stock, see the SG:42C Stock Forecast page.
More about iX Biopharma Ltd.
iX Biopharma Ltd. is a Singapore-listed specialty pharmaceutical company that develops and commercialises therapies based on its proprietary WaferiX sublingual drug delivery technology platform, with a growing focus on the U.S. longevity and wellness market and distribution through compounding pharmacies.
Average Trading Volume: 15,170,529
Technical Sentiment Signal: Buy
Current Market Cap: S$186.8M
See more data about 42C stock on TipRanks’ Stock Analysis page.